82 related articles for article (PubMed ID: 16350517)
1. Zidovudine.
Nurs Times; 2005 Nov 29-Dec 5; 101(48):33. PubMed ID: 16350517
[No Abstract] [Full Text] [Related]
2. Zidovudine (Retrovir).
Res Initiat Treat Action; 2000 Mar; 6(1):6-7. PubMed ID: 11708188
[No Abstract] [Full Text] [Related]
3. Buffalo hump: what the experts suggest.
Piliero PJ; McComsey GA
AIDS Clin Care; 2004 Mar; 16(3):22-3. PubMed ID: 15119294
[No Abstract] [Full Text] [Related]
4. Alopecia associated with zidovudine therapy.
Geletko SM; Segarra M; Mikolich DJ
Pharmacotherapy; 1996; 16(1):79-81. PubMed ID: 8700796
[TBL] [Abstract][Full Text] [Related]
5. FDA notifications. Lamivudine/zidovudine combination approved for pediatric use.
AIDS Alert; 2009 Sep; 24(9):105. PubMed ID: 19938311
[No Abstract] [Full Text] [Related]
6. FDA notifications. Generic zidovudine oral solution approved.
AIDS Alert; 2008 Aug; 23(8):90. PubMed ID: 18724489
[No Abstract] [Full Text] [Related]
7. FDA notifications. FDA approved pediatric efficacy supplement for Retrovir syrup.
AIDS Alert; 2008 Nov; 23(11):128. PubMed ID: 19043870
[No Abstract] [Full Text] [Related]
8. Unrecognized near-fatal hyperlactatemia in an HIV-infected infant exposed to nucleoside reverse transcriptase inhibitors.
Koh MT
Int J Infect Dis; 2007 Jan; 11(1):85-6. PubMed ID: 16581278
[No Abstract] [Full Text] [Related]
9. Anti-HIV agents. Dueling nukes: AZT + 3TC vs. tenofovir + FTC.
TreatmentUpdate; 2005; 17(5):5-7. PubMed ID: 17225279
[No Abstract] [Full Text] [Related]
10. Geotrichum proctitis after HIV postexposure prophylaxis.
Yánez L; Hernández JL; Saiz N; Calvo J; Ramos C; Salesa R; González-Macías J
AIDS; 2002 Aug; 16(12):1701-2. PubMed ID: 12172101
[No Abstract] [Full Text] [Related]
11. Retrovir efficacy supplement approved.
AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043841
[No Abstract] [Full Text] [Related]
12. Negligence. Liver transplant patient too late to sue Viramune maker.
AIDS Policy Law; 2003 Mar; 18(6):7. PubMed ID: 12712930
[No Abstract] [Full Text] [Related]
13. Special issue on health risks of perinatal exposure to nucleoside reverse transcriptase inhibitors.
Walker VE; Poirier MC
Environ Mol Mutagen; 2007; 48(3-4):159-65. PubMed ID: 17358025
[No Abstract] [Full Text] [Related]
14. Copackaged drug regimen approved for PEPFAR.
AIDS Alert; 2005 Apr; 20(4):46. PubMed ID: 15841530
[No Abstract] [Full Text] [Related]
15. [Severe anemia in the framework of zidovudine treatment in HIV disease].
Kis L; Heitzmann F; Keusch G; Möddel M
Praxis (Bern 1994); 2006 Jan; 95(4):119-22. PubMed ID: 16485608
[No Abstract] [Full Text] [Related]
16. ZDV link to early signs of CVD?
Bernard EJ
IAPAC Mon; 2006 Aug; 12(8):262-3. PubMed ID: 17366667
[No Abstract] [Full Text] [Related]
17. Fat wasting--AZT vs. d4T.
TreatmentUpdate; 2002 Nov; 14(8):6. PubMed ID: 12501826
[No Abstract] [Full Text] [Related]
18. FDA notifications. Zidovudine approved for pediatric use.
AIDS Alert; 2009 Sep; 24(9):105. PubMed ID: 19928325
[No Abstract] [Full Text] [Related]
19. Painless periungual pyogenic granulomata associated with reverse transcriptase inhibitor therapy in a patient with human immunodeficiency virus infection.
Williams LH; Fleckman P
Br J Dermatol; 2007 Jan; 156(1):163-4. PubMed ID: 17199585
[No Abstract] [Full Text] [Related]
20. FDA notifications. FDA approval for generic lamivudine/zidovudine.
AIDS Alert; 2008 Jan; 23(1):12. PubMed ID: 18572476
[No Abstract] [Full Text] [Related]
[Next] [New Search]
